High-protein, lean beef diet achieved similar weight loss, glucose control as normal-protein diet with no red meat.
A study was conducted to determine if tirzepatide therapy is safe and effective for weight reduction in patients with diabetes.
A study examined the effect of depression on cardiovascular and all-cause mortality in individuals with type 2 diabetes.
Researchers examined the effect of a home-based resistance exercise regimen on glycated HbA1c levels, muscle strength, and body composition in individuals with type 2 diabetes.
Researchers sought to examine the effect of glucose-lowering medications on cardiovascular and renal outcomes in Hispanic patients.
Genetic evidence does not support protective effects of modest alcohol consumption on obesity traits, T2D.
More than half of patients in remission 6 years after surgery, regardless of weight loss.
More than 1.31 billion projected to have diabetes by 2050, with almost half of countries having age-standardized rate greater than 10%.
Omnipod GO is a tubeless and waterproof insulin delivery system.
Afternoon exercise group had greatest reduction in HbA1c at year 1 among adults with overweight or obesity and type 2 diabetes.
The FDA does not review compounded drugs for safety, effectiveness, or quality; compounded medications are not FDA-approved
Afternoon high intensity exercise may have a greater effect on lowering blood glucose levels in patients with diabetes than morning high intensity interval training.
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Increased hazard ratio noted for all-cause mortality, CVD incidence and mortality for higher sugar-sweetened beverage intake.
Researchers investigated the role of glucose control on multiple cardiovascular disease-related events in patients with type 2 diabetes.
Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.
Obesity experts discuss how semaglutide and tirzepatide are changing the treatment landscape and challenges affecting access including drug shortages, inappropriate prescribing, insurance coverage, and cost.
Those with type 1 diabetes are least likely to increase physical activity, reduce caloric intake to manage overweight or obesity.
Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure.
Obesity experts discuss the cost of newer obesity medications (eg, GLP-1 agonists) and access issues, including Ozempic shortages.